Aridis Pharmaceuticals is a late-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapy using human monoclonal antibodies (mAbs) to treat infections. Co.'s product candidates include: AR-301, which is a human immunoglobulin 1 (IgG1) mAb targeting the gram-positive bacteria S. aureus alphatoxin; AR-320, which is a human, IgG1 monoclonal antibody targeting S. aureus alpha toxin; AR-501 (Panaecin), which is a spectrum small molecule anti-infective Co. is developing in addition to its targeted mAb product candidates; and AR-701, which is a is a cocktail of human mAbs that are directed at multiple protein epitopes on the SARS-CoV-2 virus. The ARDS average annual return since 2018 is shown above.
The Average Annual Return on the ARDS average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARDS average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARDS average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|